Acorda Therapeutics Inc ACOR:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
20.55 0.15   0.74%--353,036589.3K
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. Chart as of 04:00 PM ET 12/12/2017

Latest News Headlines for Acorda Therapeutics Inc

The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Acorda Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of January 17, 2018

NEW YORK--(BUSINESS WIRE)--December 12, 2017-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acorda Therapeutics, Inc. (NASDAQ: ACOR) who purchased shares between April 18, 2016 and November 14, 2017. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Acorda Therapeutics, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit

STEVENSON, Md.--(BUSINESS WIRE)--December 11, 2017-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Acorda Therapeutics, Inc. (Nasdaq: ACOR) ("Acorda" or the "Company") securities during the period between April 18, 2016 and November 14, 2017, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until January 17, 2018 to seek appointment as lead plaintiff.

ACOR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Acorda Therapeutics, Inc. and a Lead Plaintiff Deadline of January 17, 2018

NEW YORK--(BUSINESS WIRE)--December 11, 2017-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Acorda Therapeutics, Inc. ("Acorda") (NASDAQ: ACOR) securities between April 18, 2016 and November 14, 2017.

View more recent headlines

Peers Information HelpACOR Acorda Therapeutics Inc vs. Peers

ACOR
Acorda Therapeutics Inc
8.51%
-2.50%
Medpace Holdings Inc
Genomic Health, Inc.
0.71%
PDL BioPharma Inc
36.79%
-27.30%
China Biologic Products Holdings Inc
ACOR
Acorda Therapeutics Inc
0.00%
Medpace Holdings Inc
0.00%
Genomic Health, Inc.
0.00%
PDL BioPharma Inc
0.00%
China Biologic Products Holdings Inc
0.00%
ACOR
Acorda Therapeutics Inc
0.74%
Medpace Holdings Inc
1.71%
Genomic Health, Inc.
1.52%
PDL BioPharma Inc
0.69%
-2.67%
China Biologic Products Holdings Inc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

http://www.acorda.com

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open20.40
Previous Close20.40
Day High20.85
Day Low20.35
52 Week High3/9/2017 | 33.00
52 Week Low6/1/2017 | 13.60
% Off 52 Week High-37.73%
% Off 52 Week Low51.10%
Beta (5 Yr)1.59
Volatility Avg12/11/2017 | 71.82
10-Day Avg. Volume589,278
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)9/30/2017 | -1.21
P/E Ratio9/30/2017 | --
Market CapSmall Cap | 960.65M
Shares Outstanding46.75M
Float45.9M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

expand, down-facing arrow indicating expanded view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short5.89M
Short Ratio5.5
Short % of Float12.82%
As of 11/30/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.